MET Activation and Inhibition in Small Cell Lung Cancer
Author Information
Author(s): Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño J A, Arpí O, Salido M, Menéndez S, Grande E, Hirsch F R, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell J
Primary Institution: Hospital del Mar-Parc de Salut Mar
Hypothesis
Does MET activation predict poor outcomes in small cell lung carcinoma?
Conclusion
Inhibition of MET activation improves outcomes in small cell lung carcinoma patients.
Supporting Evidence
- 54% of SCLC tumors showed total MET overexpression.
- 43% of SCLC tumors showed p-MET overexpression.
- Patients with p-MET overexpression had a median overall survival of 132 days.
Takeaway
This study found that a protein called MET makes small cell lung cancer worse, but blocking it can help patients feel better.
Methodology
The study evaluated MET gene status and protein expression in SCLC cell lines and human samples, using a MET inhibitor to assess its effects.
Limitations
The study was limited to a small sample size and focused on specific mutations.
Participant Demographics
{"median_age":65,"gender_distribution":{"female":12,"male":88},"smoking_history":{"never":1,"former":29,"current":70},"clinical_stage":{"limited":42,"extensive":54}}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website